Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
- Registration Number
- NCT02321878
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1092
Inclusion Criteria
- Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)
- Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral anti-diabetes drug) other than SU (sulfonylurea)
- Male or female, no age limitation
Exclusion Criteria
- Previous participation in this study or NN2211-3772 Participation is defined as informed consent obtained for this study or enrolment for NN2211-3772
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Liraglutide liraglutide -
- Primary Outcome Measures
Name Time Method Number of AEs (adverse events) Week 0-52
- Secondary Outcome Measures
Name Time Method Number of adverse reactions (ARs) Week 0-52 Change in HbA1c (glycosylated haemoglobin) Week 0, week 52
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇯🇵Tokyo, Japan